Dominick Colangelo
Chief Executive Officer at VERICEL CORPORATION
Net worth: 10 M $ as of 30/04/2024
Dominick Colangelo active positions
| Companies | Position | Start | End |
|---|---|---|---|
| VERICEL CORPORATION | Director/Board Member | 01/03/2013 | - |
| Chief Executive Officer | 01/03/2013 | - | |
| President | 01/03/2013 | - | |
| TREVI THERAPEUTICS, INC. | Director/Board Member | 29/06/2020 | - |
| Independent Dir/Board Member | 29/06/2020 | - |
Career history of Dominick Colangelo
Former positions of Dominick Colangelo
| Companies | Position | Start | End |
|---|---|---|---|
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Director/Board Member | 23/02/2011 | 15/05/2012 |
| Chief Executive Officer | 01/12/2008 | 15/05/2012 | |
| President | 01/12/2008 | 15/05/2012 | |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Chief Operating Officer | 01/01/2005 | 11/12/2008 |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Chief Investment Officer | - | 07/12/2005 |
| Private Equity Investor | - | 07/12/2005 | |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/1995 | - |
Training of Dominick Colangelo
| State University of New York at Buffalo | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Statistics
International
| United States | 9 |
Operational
| Director/Board Member | 3 |
| Chief Executive Officer | 2 |
| President | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| VERICEL CORPORATION | Health Technology |
| TREVI THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Finance |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Dominick Colangelo
- Experience